Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05423379 · ClinicalTrials.gov registry record

XIENCE Skypoint Large Vessel Post Approval Study

A clinical trial of Coronary Artery Disease, sponsored by Abbott Medical Devices.

Active
Registry status
102
Enrollment target
18
Study locations

NCT05423379 is a study of Coronary Artery Disease that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 102 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05423379, a study of Coronary Artery Disease, is active but no longer recruiting, sponsored by Abbott Medical Devices.

ACTIVE NOT RECRUITING
Registry status
102 participants
Enrollment target
18
Study locations

Study Summary

SPIRIT XLV PAS is a prospective, single arm, multi-center, US and OUS post-approval observational study to evaluate the continued safety and effectiveness of the XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) Large Vessel (LV) sizes (diameter 4.5 mm and 5.0 mm) during commercial use in a real-world setting.

Conditions Studied

Coronary Artery Disease

Interventions

  • DEVICE XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS)

Study Locations (18)

Texas

  • Hendrick Medical Center - Abilene
  • Austin Heart - Austin
  • The Heart Hospital Baylor Plano - Plano
  • Shannon Clinic - San Angelo

Florida

  • Memorial Hospital Jacksonville - Jacksonville
  • Tallahassee Research Institute - Tallahassee

South Carolina

  • Anmed Health - Anderson
  • Greenville Health System - Greenville

Other

  • Hospital Universitario Marqués de Valdecilla - Santander
  • Hospital Virgen de Rocio - Seville

Arkansas

  • Arkansas Heart Hospital - Little Rock

Kansas

  • Via Christi Regional Medical Center - St. Francis Campus - Wichita

Nebraska

  • Bryan Heart - Lincoln

New York

  • Lenox Hill Hospital - New York

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2022-09-14
Est. Completion 2027-08-30

Sponsor

Abbott Medical Devices

261 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05423379

The ClinicalTrials.gov registry entry for NCT05423379 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (92% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) is the first listed.

NCT05423379 reports 18 study locations spanning 12 distinct geographic areas - top geographies include Texas, Florida, South Carolina.

Frequently Asked Questions

What is clinical trial NCT05423379 about?

NCT05423379 is a clinical study titled "XIENCE Skypoint Large Vessel Post Approval Study". SPIRIT XLV PAS is a prospective, single arm, multi-center, US and OUS post-approval observational study to evaluate the continued safety and effectiveness of the XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) Large Vessel (LV) sizes (diameter 4.5 mm and 5.0 mm) during ...

What is the current status of trial NCT05423379?

This trial is currently active not recruiting. The enrollment target is 102 participants. The study started on 2022-09-14. Estimated completion is 2027-08-30.

What conditions does trial NCT05423379 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT05423379?

The interventions under investigation include: XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) (DEVICE).

Who is sponsoring clinical trial NCT05423379?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05423379 being conducted?

This trial has 18 study locations across Arkansas, Florida, Kansas, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Coronary Artery Disease

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.